Oncolys BioPharma (TSE:4588) E10: 円0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4588 Oncolys BioPharma Inc TSE:4588
40 GF Score
Price 円2,501.00
GF Value 円363.33
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oncolys BioPharma E10?

Oncolys BioPharma TSE:4588 -0.83% 40 E10 is 円0.00 as of Dec. 2025. GuruFocus rates TSE:4588 with a GF Score™ of 40/100 and a GF Value™ of 円363.33 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Oncolys BioPharma's adjusted earnings per share data for the three months ended in Dec. 2025 was 円0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is 円0.00 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-14), Oncolys BioPharma's current stock price is 円2501.00. Oncolys BioPharma's E10 for the quarter that ended in Dec. 2025 was 円0.00. Oncolys BioPharma's Shiller PE Ratio of today is .


Oncolys BioPharma  (TSE:4588) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Oncolys BioPharma E10 Related Terms


Oncolys BioPharma E10 Historical Data

* Premium members only.

The historical data trend for Oncolys BioPharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolys BioPharma E10 Chart

Oncolys BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -103.48 0.00 0.00

Oncolys BioPharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -108.27 -108.32 0.00 0.00

TSE:4588 vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Oncolys BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolys BioPharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncolys BioPharma's Shiller PE Ratio falls into.


TSE:4588
40GF Score
Oncolys BioPharma Inc TSE:4588
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncolys BioPharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncolys BioPharma's adjusted earnings per share data for the three months ended in Dec. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0/113.0000*113.0000
=0.000

Current CPI (Dec. 2025) = 113.0000.

Oncolys BioPharma Quarterly Data

per share eps CPI Adj_EPS
201509 -21.200 98.500 -24.321
201512 -27.893 98.100 -32.130
201603 -20.280 97.900 -23.408
201606 -25.230 98.100 -29.062
201609 -34.020 98.000 -39.227
201612 -21.650 98.400 -24.862
201703 -25.910 98.100 -29.845
201706 -27.980 98.500 -32.099
201709 -23.920 98.800 -27.358
201712 -28.420 99.400 -32.308
201803 -28.090 99.200 -31.998
201806 -29.807 99.200 -33.954
201809 -21.420 99.900 -24.229
201812 -25.240 99.700 -28.607
201903 -26.910 99.700 -30.500
201906 6.104 99.800 6.911
201909 -22.660 100.100 -25.580
201912 -22.820 100.500 -25.658
202003 -19.960 100.300 -22.487
202006 -26.470 99.900 -29.941
202009 -61.210 99.900 -69.237
202012 -37.940 99.300 -43.174
202103 -22.360 99.900 -25.292
202106 -17.331 99.500 -19.682
202109 -18.978 100.100 -21.424
202112 -37.080 100.100 -41.859
202203 -18.980 101.100 -21.214
202206 -13.940 101.800 -15.474
202209 -15.280 103.100 -16.747
202212 -18.110 104.100 -19.658
202303 -18.690 104.400 -20.230
202306 -31.470 105.200 -33.803
202309 -22.990 106.200 -24.462
202312 -35.770 106.800 -37.847
202403 -18.240 107.200 -19.227
202406 -18.720 108.200 -19.550
202412 0.000 110.700 0.000
202503 -32.660 111.100 -33.219
202506 -20.190 111.700 -20.425
202512 0.000 113.000 0.000

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of 円0.00 mean?
Oncolys BioPharma (TSE:4588) has a E10 of 円0.00 as of Dec. 2025. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Oncolys BioPharma and its competitors.
Is Oncolys BioPharma's E10 too high?
Oncolys BioPharma's current E10 is 円0.00. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's E10 compare to VRTX and REGN?
Oncolys BioPharma's E10 of 円0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Oncolys BioPharma and its competitors. Oncolys BioPharma's current E10 is 円0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円363.33, compared to a current price of 円2,501.00 — trading 588.4% above its estimated fair value. The current E10 is 円0.00. Oncolys BioPharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current E10 is 円0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?

Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued. The current stock price of 円2,501.00 is trading 588.4% above its estimated GF Value™ of 円363.33. GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.

Key valuation signals for TSE:4588:

  • E10: 円0.00
  • GF Value™: 円363.33 vs. price of 円2,501.00 (588.4% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncolys BioPharma Business Description

Address 4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score

Get the complete analysis for TSE:4588

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,501.00
Price
円363.33
GF Value